Prevention of vaginal atrophy after treatment for tumors of the female reproductive system

This article discusses the problems of rational pharmacotherapy in women with vulvovaginal atrophy developed after gynecological operations or during combination treatment for tumors of the female reproductive system. The range of adverse effects makes long-term treatment of these patients necessary not only to relieve the symptoms, but also to prevent possible problems, such as sexual dysfunction, postcoital bleeding, and recurrent urinary tract infections. Considering the pathogenesis of vulvovaginal atrophy associated with many unpleasant symptoms, such as dryness, burning, and dyspareunia resultedfrom low levels of estrogen, we have provided a rationale for topical application of Flamen® gel with subsequent restoration of vaginal pH. Effective relief of pain syndrome, which usually manifested itself with burning, itching, swelling, and hyperemia of the vaginal vestibule and perineal tissues, ensured maximum compliance during treatment and allowed the achievement of not only clinical, but also pathogenetic effect